PRO 131921

Drug Profile

PRO 131921

Alternative Names: PRO-131921

Latest Information Update: 23 Dec 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 08 Dec 2009 Safety, pharmacokinetics and efficacy data from a phase I/II trial in Non-Hodgkin's lymphoma were presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009)
  • 19 Jun 2009 Discontinued - Phase-I/II for Non-Hodgkin's lymphoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top